Cost-effectiveness of stroke treatments and secondary preventions

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) James V. Freeman et al.   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

(2011) Shimoli V. Shah et al.   CIRCULATION

Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke

(2011) Peter M Rothwell et al.   LANCET

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

(2011) Anuraag Kansal et al.   THROMBOSIS AND HAEMOSTASIS

Heart Disease and Stroke Statistics—2011 Update

(2010) Véronique L. Roger et al.   CIRCULATION

The Economic Case for New Stroke Thrombolytics

(2010) S. C. Johnston   STROKE

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack

(2010) Karen L. Furie et al.   STROKE

Cost-effectiveness of warfarin: Trial versus “real-world” stroke prevention in atrial fibrillation

(2009) Sonja V. Sorensen et al.   AMERICAN HEART JOURNAL

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial

(2009) Thitima Kongnakorn et al.   VALUE IN HEALTH

Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

(2008) Ralph L. Sacco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Model-Based Cost-Effectiveness Analyses for the Treatment of Acute Stroke Events: A Review and Summary of Challenges

(2008) Stephanie R. Earnshaw et al.   VALUE IN HEALTH